Topical ocular delivery of fluoroquinolones

Bibliography

• Henderer JD, Raprano CJ. Ocular pharmacology. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw-Hill, New York, USA; 2005. pp. 1707-37
   Google Scholar
• Lemke TL, Williams DA, Rosche VF, Zito SW. editor. Foye's principles of medicinal chemistry. 6th edition. Lippincott Williams & Wilkins, Baltimore, USA; 2008
   Google Scholar
• Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000;46:669-83
   PubMed Web of Science ®Google Scholar
• Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000;16:5-15
   PubMed Web of Science ®Google Scholar
• Neil MJO. editor. The Merck index: an Encyclopedia of chemicals, drugs, and biologicals. 14th edition. Merck & Co Inc, Whitehouse Station, NJ, USA; 2006
   Google Scholar
• Ross DL, Riley CM. Physicochemical properties of the fluoroquinolone antimicrobials. II. Acid ionization constants and their relationship to structure. Int J Pharm 1992;83:267-72
   Google Scholar
• Tai MC, Lu DW,Chiang CH. Corneal and scleral permeability of quinolones – a pharmacokinetic study. J Ocul Pharmacol Ther 2003;19:547-54
   PubMed Web of Science ®Google Scholar
• Castillo A, Benitez del Castillo JM, Toledano N, Deposits of topical norfloxacin in the treatment of bacterial keratitis. Cornea 1997;16:420-3
   PubMed Web of Science ®Google Scholar
• Giannola LI, de Caro V, Giandalia G, Ocular gelling microspheres: in vitro precorneal retention time and drug permeation through reconstituted corneal epithelium. J Ocul Pharmacol Ther 2008;24:186-96
   PubMed Web of Science ®Google Scholar
• Rao V, Somashekar S. Preparation and Evaluation of ocular inserts containing norfloxacin. Turk J Med Sci 2004;34:239-46
   Google Scholar
• Alvarez-Lorenzo C, Yañez F, Barreiro-Iglesias R, Concheiro A. Imprinted soft contact lenses as norfloxacin delivery systems. J Control Release 2006;113:236-44
   PubMed Web of Science ®Google Scholar
• Abdelbary G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharm Develop Technol 2011;16:44-56
   PubMed Web of Science ®Google Scholar
• Adenis JP, Colin J, Verin P, Ciprofloxacin ophthalmic solution in the treatment of conjunctivitis and blepharitis: a comparison with fusidic acid. Eur J Ophthalmol 1996;6:368-74
   PubMedGoogle Scholar
• Hendrix DV, Stuffle JL, Cox SK. Pharmacokinetics of topically applied ciprofloxacin in equine tears. Vet Ophthalmol 2007;10:344-7
   PubMed Web of Science ®Google Scholar
• Oztürk F, Kurt E, Inan UU, The effects of prolonged acute use and inflammation on the ocular penetration of topical ciprofloxacin. Int J Pharm 2000;204:97-100
   PubMed Web of Science ®Google Scholar
• Dajcs JJ, Moreau JM, Thibodeaux BA, Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis. Cornea 2001;20:878-80
   PubMed Web of Science ®Google Scholar
• Jain D, Carvalho E, Banerjee R. Biodegradable hybrid polymeric membranes for ocular drug delivery. Acta Biomaterialia 2010;6:1370-9
   PubMed Web of Science ®Google Scholar
• Jain D, Carvalho E, Banthia AK, Banerjee R. Development of polyvinyl alcohol-gelatin membranes for antibiotic delivery in the eye. Drug Dev Ind Pharm 2011;37:167-77
   PubMed Web of Science ®Google Scholar
• Fukuda M, Sasaki K. In vitro topically applied fluoroquinolone penetration into anterior chamber. Nippon Ganka Gakkai Zasshi 1995;99:532-6
   PubMedGoogle Scholar
• Ke TL, Cagle G, Schlech B, Ocular bioavailability of ciprofloxacin in sustained release formulations. J Ocul Pharmacol Ther 2001;17:555-63
   PubMed Web of Science ®Google Scholar
• Charoo NA, Kohli K, Ali A. Preparation of in situ-forming ophthalmic gels of ciprofloxacin hydrochloride for the treatment of bacterial conjunctivitis: in vitro and in vivo studies. J Pharm Sci 2003;92:407-13
   PubMed Web of Science ®Google Scholar
• Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv 2003;10:185-91
   PubMed Web of Science ®Google Scholar
• Jain SP, Shah SP, Rajadhyaksha NS, In situ ophthalmic gel of ciprofloxacin hydrochloride for once a day sustained delivery. Drug Dev Ind Pharm 2008;34:445-52
   PubMed Web of Science ®Google Scholar
• Weyenberg W, Vermeire VA, Dhondt MM, Ocular bioerodible minitablets as strategy for the management of microbial keratitis. Invest Ophthalmol Vis Sci 2004;45:3229-33
   PubMed Web of Science ®Google Scholar
• Charoo NA, Kohli K, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies. Drug Dev Ind Pharm 2003;29:215-21
   PubMed Web of Science ®Google Scholar
• Samanta A, Ghosal SK. Prolonged delivery of ciprofloxacin hydrochloride from hydrophilic ocular inserts. Acta Pol Pharm 2004;61:343-9
   PubMedGoogle Scholar
• Mundada AS, Shrikhande BK. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug Dev Ind Pharm 2006;32:443-8
   PubMed Web of Science ®Google Scholar
• Mundada AS, Shrikhande BK. Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res 2008;33:469-75
   PubMed Web of Science ®Google Scholar
• Budai L, Hajdú M, Budai M, Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm 2007;343:34-40
   PubMed Web of Science ®Google Scholar
• Mehana MM, Elmaradny HA, Samala MW. Mucoadhesive liposomes as ocular delivery system: Physical, microbiological and in vivo assessment. Drug Dev Ind Pharm 2010;36:108-18
   PubMed Web of Science ®Google Scholar
• Martinez M, McDermott P, Walker R. Pharmacology of fluoroquinolones: a perspective for the use in domestic animals. Vet J 2006;172:10-28
   Google Scholar
• Cochereau-Massin I, Bauchet J, Faurisson F, Ocular kinetics of pefloxacin after intramuscular administration in albino and pigmented rabbits. Antimicrob Agents Chemother 1991;35:1112-15
   PubMed Web of Science ®Google Scholar
• Marrakchi-Benjaafar S, Cochereau I, D'Hermies F, Pocidalo JJ. Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits. Antimicrob Agents Chemother 1995;39:834-8
   PubMed Web of Science ®Google Scholar
• Sultana Y, Aqil M, Ali A, Zafar S. Evaluation of Carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol. 2006;11:313-19
   Google Scholar
• Sultana Y, Jha MC, Ali A, Aqil M. A three-way comparative study on the efficacy of twin sol to gel systems and marketed eye drops of pefloxacin mesylate. J Ocul Pharmacol Ther 2004;20:363-71
   PubMed Web of Science ®Google Scholar
• Sultana Y, Aqil M, Ali A. Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation. Acta Pharm 2005;55:305-14
   PubMedGoogle Scholar
• Ooshi M, Oomono A, Sakaue F, Studies on intraocular penetration of. NY-198(lomefloxacin) eye drops. Acta Soc Ophthalmol Jpn 1988;11:1825-32
   Google Scholar
• Zhang Y, Chen Y, Chen Z. Intraocular penetration of topical lomefloxacin in rabbit's eyes. Zhonghua Yan Ke Za Zhi 1998;34:211-14
   PubMedGoogle Scholar
• Velpandian T, Gupta SK, Gupta YK, Comparative studies on topical lomefloxacin and ciprofloxacin on ocular kinetic and experimental corneal ulcer. J Ocul Pharmacol Ther 1999;15:505-11
   PubMed Web of Science ®Google Scholar
• Erjongmanee S, Kasetsuwan N, Phusitphoykai N, Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis. J Med Assoc Thai 2004;87:S83-90
   PubMedGoogle Scholar
• Snir M, Hasanreisoglu M, Friling R, Postoperative lomefloxacin 0.3% prophylaxis in strabismus surgery. Curr Eye Res 2008;33:819-25
   PubMed Web of Science ®Google Scholar
• Portoles M, Iqual A, Juach A, Nos-Barbera S. In vitro toxicity of lomefloxacin in rabbit corneal epithelial cell cultures. Lens Eye Toxi Res 1990;4:469-80
   Google Scholar
• Tian X, Iwatsu M, Kanai A. Disposable 1-day Acuvue contact lenses for the delivery of lomefloxacin to rabbits eyes. CLAO J 2001;27:212-15
   PubMedGoogle Scholar
• Ahuja M, Singh G, Majumdar DK. Effect of formulation parameters on corneal permeability of ofloxacin. Sci Pharm 2008;76:505-14
   Google Scholar
• Di Colo G, Zambito Y, Burgalassi S, Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int J Pharm 2004;273:37-44
   PubMed Web of Science ®Google Scholar
• Felt O, Baeyens V, Buri P, Gurny R. Delivery of antibiotics to the eye using a positively charged polysaccharide as vehicle. AAPS PharmSci 2001;3:E34
   PubMedGoogle Scholar
• Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 2001;73:205-11
   PubMed Web of Science ®Google Scholar
• Di Colo G, Burgalassi S, Chetoni P, Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Int J Pharm 2001;215:101-11
   PubMed Web of Science ®Google Scholar
• Di Colo G, Zambito Y, Burgalassi S, Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide). Int J Pharm 2002;48:115-22
   Google Scholar
• Oztürk F, Kortunay S, Kurt E, The effect of long-term use and inflammation on the ocular penetration of topical ofloxacin. Curr Eye Res 1999;19:461-4
   PubMed Web of Science ®Google Scholar
• Yu-Speight AW, Kern TJ, Erb HN. Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract surgery. Vet Ophthalmol 2005;8:181-7
   PubMed Web of Science ®Google Scholar
• Cekiç O, Batman C, Totan Y, Aqueous humour levels of topically applied ciprofloxacin and ofloxacin in the same subjects. Eye 1999;13:656-9
   Google Scholar
• Taravella MJ, Balentine J, Young DA, Stepp P. Collagen shield delivery of ofloxacin to the human eye. J Cataract Refract Surg 1999;25:562-5
   PubMed Web of Science ®Google Scholar
• De Sarro A, Zappala M, Chimirri A, Quinolones potentiate cefazolin-induced seizures in DAB/2 mice. Antimicrob Agents Chemother 1993;37:1497-503
   PubMed Web of Science ®Google Scholar
• Wise R, Andrews JM, Matthews R, Wolstenholme M. The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother 1992;29:649-60
   PubMed Web of Science ®Google Scholar
• Ghelardi E, Tavanti A, Davini P, A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis. Antimicrob Agents Chemother 2004;48:3396-401
   PubMed Web of Science ®Google Scholar
• Burgalassi S, Cappello B, Chetoni P, Rufloxacin eyedrops: effect of different formulations on ocular pharmacokinetics in rabbits. Eur J Ophthalmol 2006;16:311-17
   PubMed Web of Science ®Google Scholar
• Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones. Am J Health Syst Pharm 1997;54:2569-84
   PubMed Web of Science ®Google Scholar
• Wimer SM, Schoonover L, Garrison MW. Levofloxacin: a therapeutic review. Clin Ther 1998;20:1049-70
   PubMed Web of Science ®Google Scholar
• Gerbino PP. editor. Remington: The science and practice of pharmacy. 21st edition. Lippincott Williams & Wilkins, Philadelphia, USA; 2005
   Google Scholar
• Ross DL, Riley CM. Aqueous solubilities of some variously substituted quinolones antimicrobials. Int J Pharm 1990;63:237-50
   Web of Science ®Google Scholar
• Kawazu K, Midori Y, Shiono H, Ota A. Characterization of the carrier-mediated transport of levofloxacin, a fluoroquinolone antimicrobial agent, in rabbit cornea. J Pharm Pharmacol 1999;51:797-801
   PubMed Web of Science ®Google Scholar
• Cai J, Zhang Y, Du W, Nan K. Preparation and in vitro release of spray-dried chitosan microspheres for levofloxacin delivery. J Control Release 2011;152:e70-1
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Takahashi H, Usui M. Pharmacokinetic parameters of ofloxacin and levofloxacin ophthalmic solutions. [In Japanese] Atarsii Gannka 1995;12:791-4
   Google Scholar
• Fukuda M, Inoue A, Sasaki K, Takahashi N. The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. Jpn J Ophthalmol 2004;48:93-6
   PubMed Web of Science ®Google Scholar
• Healy DP, Holland EJ, Nordlund ML, Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea 2004;23:255-63
   PubMed Web of Science ®Google Scholar
• Bucci Jr FA. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Am J Ophthalmol 2004;137:308-12
   PubMed Web of Science ®Google Scholar
• Yamada M, Mochizuki H, Yamada K, Aqueous humor levels of topically applied levofloxacin, norfloxacin, and lomefloxacin in the same human eyes. J Cataract Refract Surg 2003;29:1771-5
   PubMed Web of Science ®Google Scholar
• Yamada M, Ishikawa K, Mochizuki H, Kawai M. Corneal penetration of simultaneously applied topical levofloxacin, norfloxacin and lomefloxacin in human eyes. Acta Ophthalmol Scand 2006;84:192-6
   PubMedGoogle Scholar
• Liu W, Liu QF, Perkins R, Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinilone antimicrobials. Antimicrob Agents Chemother 1998;42:1417-23
   PubMed Web of Science ®Google Scholar
• Satia MC, Mody VD, Modi RI, Pharmacokinetics of topically appied sparfloxacin in rabbits. Indian J Ophthalmol 2005;53:177-81
   Google Scholar
• Fukuda M, Sasaki K. Differences between albino and pigmented rabbit eyes in the intraocular pharmacokinetics of sparfloxacin. Drugs 1995;49:314-16
   PubMedGoogle Scholar
• Cochereau-Massin I, Bauchet J, Marrakchi-Benjaafar S, Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. Antimicrob Agents Chemother 1993;37:633-6
   PubMed Web of Science ®Google Scholar
• Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997;39(B):1-14
   PubMedGoogle Scholar
• Barequet IS, Denton P, Osterhout GJ, Treatment of experimental bacterial keratitis with topical trovafloxacin. Arch Ophthalmol 2004;122:65-9
   PubMed Web of Science ®Google Scholar
• Ng EW, Joo MJ, Au Eong KG, Ocular toxicity of intravitreal trovafloxacin in the pigmented rabbit. Curr Eye Res 2003;27:387-93
   PubMed Web of Science ®Google Scholar
• Rathore MS, Majumdar DK. Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS PharmSciTech 2006;7:57
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb Co. New drug application for Tequin (Gatifloxacin Tablets and Injections). Environmental assessment. Center for drug evaluation and research website 2001; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-061SE2-007_Tequin_EAfonsi.pdf [Last accessed on]
   Google Scholar
• Kaliamurthy J, Nelson Jesudasan CA, Geraldine P, Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res 2005;37:117-22
   PubMed Web of Science ®Google Scholar
• Ozdek SC, Miller D, Flynn PM, Flynn HW. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections. Ocul Immunol Inflamm 2006;14:347-51
   PubMed Web of Science ®Google Scholar
• Mah FS, Romanowski EG, Kowalski RP, Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model. Cornea 2007;26:585-8
   PubMed Web of Science ®Google Scholar
• Wada T, Naka H, Tokushige H, Treatment of rabbit corneal infections with ophthalmic gatifloxacin: a concentration dependence study. Adv Ther 2004;21:1-12
   PubMed Web of Science ®Google Scholar
• De Castro LE, Sandoval HP, Bartholomew LR, Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxis model. J Ocul Pharmacol Ther 2006;22:132-8
   PubMed Web of Science ®Google Scholar
• Wada T, Kozai S, Tajika T, Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits. J Ocul Pharmacol Ther 2008;24:278-89
   PubMed Web of Science ®Google Scholar
• Wada T, Kida T, Inoue T, Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis. Ophthalmic Res 2008;40:54-60
   PubMed Web of Science ®Google Scholar
• Liu Z, Li J, Nie S, Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 2006;315:12-17
   PubMed Web of Science ®Google Scholar
• Donnenfeld RS, Perry HD, Solomon R, A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model. Eye Contact Lens 2006;32:46-50
   PubMedGoogle Scholar
• Slade DS, Friday JW, Snyder RW, Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model. J Cataract Refract Surg 2007;33:888-92
   PubMed Web of Science ®Google Scholar
• Kesavan K, Nath G, Jayanta K, Pandit JK. Sodium alginate based mucoadhesive system for gatifloxacin and its in vitro antibacterial activity. Sci Pharm 2010;78:941-57
   PubMedGoogle Scholar
• Gonjari ID, Karmarkar AB, Khade TS, Use of factorial design in formulation and evaluation of ophthalmic gels of gatifloxacin: comparison of different mucoadhesive polymers. Drug Discov Ther 2010;4:423-34
   PubMedGoogle Scholar
• Liu Z, Yang XG, Li X, Study on the ocular pharmacokinetics of ion-activated in situ gelling ophthalmic delivery system for gatifloxacin by microdialysis. Drug Dev Ind Pharm 2007;33:1327-31
   PubMed Web of Science ®Google Scholar
• Kalam MA, Sultana Y, Samad A, Gelrite based in vitro gelation ophthalmic drug delivery system of gatifloxacin. J Dispersion SciTechnol 2008;29:89-96
   Google Scholar
• Motwani SK, Chopra S, Talegaonkar S, Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization. Eur J Pharm Biopharm 2008;68:513-25
   PubMed Web of Science ®Google Scholar
• Kalam MA, Sultana Ali A, Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Targeting 2010;18:191-204
   PubMed Web of Science ®Google Scholar
• Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol Pharm 2010;7:576-85
   PubMed Web of Science ®Google Scholar
• Langlois MH, Montagut M, Dubost JP, Protonation equilibrium and lipophilicity of moxifloxacin. J Pharm Biomed Anal 2005;37:389-93
   PubMed Web of Science ®Google Scholar
• Pawar PK, Majumdar DK. Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas. AAPS PharmSciTech 2006;7:E13
   PubMedGoogle Scholar
• Shastri DH, Prajapati ST, Patel LD. Design and development of thermoreversible ophthalmic in situ hydrogel of moxifloxacin HCl. Curr Drug Deliv 2010;7:238-43
   PubMedGoogle Scholar
• Tauber S, Cupp G, Garber R, Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. Adv Ther 2011;28:566-74
   PubMed Web of Science ®Google Scholar
• Nanjwade BK, Deshmukh RV, Gaikwad KR, Formulation and evaluation of micro hydrogel of moxifloxacin hydrochloride. Eur J Drug Metab Pharmacokinet 2012;37:117-23
   PubMed Web of Science ®Google Scholar
• Pawar PK, Majumdar DK. In vitro permeation characteristics of moxifloxacin from oil drops through excised goat, sheep, buffalo and rabbit corneas. Pharmazie 2007;62:853-7
   PubMed Web of Science ®Google Scholar
• Katz HR, Masket S, Lane SS, Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea 2005;24:955-8
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Shah GK, Chi J, Prince RA. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J Cataract Refract Surg 2005;31:2142-6
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Mieler WE, Shah GK, Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. Trans Am Ophthalmol Soc 2004;102:149-55
   PubMedGoogle Scholar
• Oliveira AD, D'Azevedo PA, Francisco W. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo. Brazil Cornea 2007;26:194-8
   PubMed Web of Science ®Google Scholar
• Kim SY, Lim JA, Choi JS, Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro. Cornea 2007;26:720-5
   PubMed Web of Science ®Google Scholar
• Abshire R, Cockrum P, Crider J, Schlech B. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Clin Ther 2004;26:191-6
   PubMed Web of Science ®Google Scholar
• Dajcs JJ, Thibodeaux BA, Marquart ME, Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother 2004;48:1948-52
   PubMed Web of Science ®Google Scholar
• Thibodeaux BA, Dajcs JJ, Caballero AR, Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. Curr Eye Res 2004;28:337-42
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Romanowski EG, Mah FS, Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol 2004;138:33-7
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Romanowski EG, Mah FS, Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol 2005;140:497-504
   PubMed Web of Science ®Google Scholar
• Constantinou M, Daniell M, Snibson GR, Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology 2007;114:1622-9
   PubMed Web of Science ®Google Scholar
• Levine JM, Noecker RJ, Lane LC, Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J Cataract Refract Surg 2004;30:2177-82
   PubMed Web of Science ®Google Scholar
• Yağci R, Oflu Y, Dinçel A, Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye 2007;21:990-4
   PubMed Web of Science ®Google Scholar
• Solomon R, Donnenfeld ED, Perry HD, Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;112:466-9
   PubMed Web of Science ®Google Scholar
• McCulley JP, Caudle D, Aronowicz JD, Shine WE. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006;113:955-9
   PubMed Web of Science ®Google Scholar
• Holland EJ, Lane SS, Kim T, Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea 2008;27:314-19
   PubMed Web of Science ®Google Scholar
• Kleinmann G, Apple DJ, Chew J, Hydrophilic acrylic intraocular lens as a drug-delivery system: pilot study. J Cataract Refract Surg 2006;32:652-4
   PubMed Web of Science ®Google Scholar
• Kleinmann G, Larson S, Neuhann IM, Intraocular concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shields. Cornea 2006;25:209-13
   PubMed Web of Science ®Google Scholar
• Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 2005;112:1992-6
   PubMed Web of Science ®Google Scholar
• Bucci FA, Amico LM, Evans RE. Antimicrobial efficacy of prophylactic gatifloxacin 0.3 % and moxifloxacin 0.5 % in patients undergoing phacoemulsification surgery. Eye Cont Lens 2008;34:39-42
   PubMed Web of Science ®Google Scholar